RCS - ValiRx PLC - ValiRx to exhibit at the UK Investor Show <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

22/04/2016 10:05

RNS Number : 0544W
ValiRx PLC
22 April 2016
ValiRx Plc
("ValiRx"or "theCompany")
COMMUNICATIONS UPDATE
"ValiRx to exhibit at the UK Investor Show"
London, UK, 22nd April 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that the Company will be exhibiting and presenting at the UK Investor Show 2016, which will take place at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London, SW1P 3EE on Saturday 30th April 2016.
Dr Satu Vainikka, Chief Executive Officer of ValiRx will make a presentation and a Dragon's Pitch during the day.
Tickets to the event can be found through the following link:
www.ukinvestorshow.com
Representatives of the Company's management team will also be in attendance at the show to welcome existing and potential investors. 
About ValiRx Plc 
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases. It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimizing financial exposure andrunning a set of projects todefined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.
*** ENDS ***
For further information on the Company, visit: www.valirx.com:
ValiRx plc
Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Manager
Tel: +44 (0) 7736 564 686
mark.treharne@valirx.com


Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking)


This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAUUVWRNWASURR